The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > Reimbursement Listing in 2018-2019
Reimbursement Listing in 2018-2019
-
Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
-
Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
-
Keytruda to Get 17.5% Price Cut in February
November 13, 2019
-
Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
-
Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
-
Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
-
Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
-
Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
-
Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
-
Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
-
Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
-
As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing
May 16, 2019
-
Japan OKs Listing of Trelegy, Erleada, and More; GSK’s COPD Hopeful to Face Cost-Effectiveness Analysis
May 15, 2019
-
Kymriah Gets 33.5 Million Yen Price Tag, Peak Sales Put at 7.2 Billion Yen
May 15, 2019
-
Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
-
Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
-
Gilead’s HIV Triplet Biktarvy to Join NHI Price List on April 3
March 27, 2019
-
Japan OKs Listing of Evenity, Tarlige, Epclusa, and More on Feb. 26
February 20, 2019
-
Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
-
ViiV’s HIV Drug Juluca to Join NHI Price List on Dec. 12
December 5, 2018
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…